Enovis Corporation $ENOV Shares Acquired by MGO One Seven LLC

MGO One Seven LLC grew its holdings in Enovis Corporation (NYSE:ENOV) by 39.7% during the 2nd quarter, Holdings Channel reports. The firm owned 7,586 shares of the company’s stock after buying an additional 2,157 shares during the period. MGO One Seven LLC’s holdings in Enovis were worth $238,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Allspring Global Investments Holdings LLC grew its position in shares of Enovis by 191.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 810,771 shares of the company’s stock valued at $26,772,000 after purchasing an additional 532,648 shares during the last quarter. CWM LLC grew its position in shares of Enovis by 564.9% in the second quarter. CWM LLC now owns 3,790 shares of the company’s stock valued at $119,000 after purchasing an additional 3,220 shares during the last quarter. Lawson Kroeker Investment Management Inc. NE grew its position in shares of Enovis by 6.3% in the second quarter. Lawson Kroeker Investment Management Inc. NE now owns 227,235 shares of the company’s stock valued at $7,126,000 after purchasing an additional 13,566 shares during the last quarter. Live Oak Investment Partners grew its position in shares of Enovis by 2.5% in the second quarter. Live Oak Investment Partners now owns 26,352 shares of the company’s stock valued at $826,000 after purchasing an additional 640 shares during the last quarter. Finally, Lecap Asset Management Ltd. acquired a new stake in shares of Enovis in the second quarter valued at approximately $370,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Enovis

In other news, CFO Phillip Benjamin (Ben) Berry purchased 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The shares were purchased at an average price of $29.71 per share, with a total value of $74,275.00. Following the purchase, the chief financial officer directly owned 116,729 shares of the company’s stock, valued at approximately $3,468,018.59. This represents a 2.19% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Damien Mcdonald acquired 6,457 shares of the firm’s stock in a transaction on Thursday, September 11th. The stock was purchased at an average cost of $30.97 per share, with a total value of $199,973.29. Following the completion of the transaction, the chief executive officer owned 102,753 shares in the company, valued at $3,182,260.41. The trade was a 6.71% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders bought 12,157 shares of company stock valued at $374,760. Corporate insiders own 2.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on ENOV shares. UBS Group lowered their price target on shares of Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Canaccord Genuity Group reduced their price objective on shares of Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Needham & Company LLC reduced their price objective on shares of Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Finally, Evercore ISI reduced their price objective on shares of Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.00.

Enovis Price Performance

ENOV stock opened at $32.41 on Tuesday. The firm has a market cap of $1.85 billion, a P/E ratio of -2.27 and a beta of 1.69. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25. Enovis Corporation has a 1 year low of $25.47 and a 1 year high of $49.83. The stock has a 50-day simple moving average of $30.96 and a 200-day simple moving average of $31.53.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The firm had revenue of $383.81 million for the quarter. On average, equities analysts predict that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.